Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 2, 2009, Pages 267-273

  Inada, Seisuke ^a   Tomidokoro, Takashi ^b   Fukunari, Hiroyuki ^f   Sato, Tomomi ^b   Hatano, Toru ^b   Nishimura, Atsushi ^b   Kawauchi, Yasuyuki ^b   Nikkuni, Keiya ^b   Shimizu, Takeaki ^b   Sato, Toshiteru ^b   Yanagi, Masahiko ^c   Takahashi, Satoru ^c   Yoshida, Hideki ^d   Sugita, Minoru ^e   Hayashi, Tetsuji ^f  

^a Inada Clinic   (Japan)

^b Nagaoka Chuo General Hospital   (Japan)

^c NAGAOKA RED CROSS HOSPITAL   (Japan)

^d Yoshida Hospital   (Japan)

^e TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Department of Surgery   (Japan)

Author keywords

Advanced gastric cancer; Paclitaxel; Phase I II; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SIDE EFFECT; SKIN PIGMENTATION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; PACLITAXEL; STOMACH NEOPLASMS; TEGAFUR;

EID: 57149135364     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0736-4     Document Type: Article

References (26)

1. JA Ajani DH Ilson K Daugherty DP Kelsen 1995 Paclitaxel in the treatment of carcinoma of the esophagus Semin Oncol 22 35 40
2. Andersson H, Boman K, Ridderheim M, Rosenberg P, Sorbe B, Puistola U, Horvath G (2000) An updated analysis of a randomized study of single agent paclitaxel (P) given weekly vs every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. J Clin Oncol (Meeting Abstracts) 19: Abstract No. 1505
3. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Kimura A, Ohtsu A, Gastrointestinal Oncology Study Group/Japan Clinical Oncology G (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol (Meeting Abstracts) 25: LBA4513
4. D Cunningham N Starling S Rao T Iveson M Nicolson F Coxon G Middleton F Daniel J Oates AR Norman 2008 Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36 46
5. K Fujitani H Narahara H Takiuchi T Tsujinaka E Satomi M Gotoh M Hirao H Furukawa T Taguchi 2005 Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer Oncology 69 414 420
6. K Hirata N Horikoshi K Aiba M Okazaki R Denno K Sasaki Y Nakano H Ishizuka Y Yamada S Uno T Taguchi T Shirasaka 1999 Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug Clin Cancer Res 5 2000 2005
7. S Hironaka S Zenda N Boku A Fukutomi T Yoshino Y Onozawa 2006 Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer Gastric Cancer 9 14 18
8. S Hokita T Aikou F Miyazono S Ishigami K Aridome S Maenohara T Saihara K Suenaga H Nomura S Maeda H Takatori H Arima Y Uchikado S Natsugoe S Takao 2006 A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer Cancer Chemother Pharmacol 57 736 740
9. DH Ilson 2007 Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 25 3188 3190
10. DH Ilson RG Wadleigh LP Leichman DP Kelsen 2007 Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer Ann Oncol 18 898 902
11. Kang Y, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Philco M, Suarez T, Santamaria J (2006) Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. J Clin Oncol (Meeting Abstracts) 24: LBA4018
12. Y Kano M Akutsu S Tsunoda J Ando J Matsui K Suzuki T Ikeda Y Inoue K Adachi 1996 Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro Br J Cancer 74 704 710
13. Y Kodera S Ito Y Mochizuki S Fujitake K Koshikawa Y Kanyama T Matsui H Kojima T Takase N Ohashi M Fujiwara J Sakamoto N Akimasa 2007 A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study) Anticancer Res 27 2667 2671
14. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191 197
15. W Koizumi H Narahara T Hara A Takagane T Akiya M Takagi K Miyashita T Nishizaki O Kobayashi W Takiyama Y Toh T Nagaie S Takagi Y Yamamura K Yanaoka H Orita M Takeuchi 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221
16. W Koizumi S Tanabe K Saigenji A Ohtsu N Boku F Nagashima K Shirao Y Matsumura M Gotoh 2003 Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207 2212
17. M Markman J Hall D Spitz S Weiner L Carson L Van Le M Baker 2002 Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer J Clin Oncol 20 2365 2369
18. A Ohtsu N Boku F Tamura K Muro Y Shimada K Saigenji S Akazawa M Kitajima R Kanamaru T Taguchi 1998 An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer Am J Clin Oncol 21 416 419
19. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720
20. AD Seidman CA Hudis J Albanell W Tong I Tepler V Currie ME Moynahan M Theodoulou M Gollub J Baselga L Norton 1998 Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer J Clin Oncol 16 3353 3361
21. T Shirasaka Y Shimamoto H Ohshimo M Yamaguchi T Kato K Yonekura M Fukushima 1996 Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548 557
22. T Shirasaka Y Shimamoto M Fukushima 1993 Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004 4009
23. K Sugimachi Y Maehara N Horikoshi Y Shimada Y Sakata Y Mitachi T Taguchi 1999 An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group Oncology 57 202 210
24. Y Ueda H Yamagishi D Ichikawa J Morii K Koizumi N Kakihara M Shimotsuma A Takenaka T Yamashita H Kurioka M Nishiyama S Morita K Nakamura J Sakamoto 2005 Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer Oncology 69 261 268
25. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni A Rodrigues M Fodor Y Chao E Voznyi ML Risse JA Ajani 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991 4997
26. Y Yamada K Shirao A Ohtsu N Boku I Hyodo H Saitoh Y Miyata T Taguchi 2001 Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions Ann Oncol 12 1133 1137